SANOFI : Stifel raises its recommendation
The broker is 'reasonably optimistic that Sanofi can post a strong short-term growth cycle driven by Dupixent and Beyfortus (11% average annual EPS growth over 2024-27), followed by an improved pipeline realization phase'.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
Go to the original article.
Contact us to request a correction